Takeda Pharmaceutical (NYSE:TAK) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from an equal weight rating to an overweight rating in a research report sent to investors on Wednesday morning, Marketbeat reports.

Takeda Pharmaceutical Stock Down 3.0 %

Shares of NYSE:TAK opened at $14.74 on Wednesday. The company has a market capitalization of $46.89 billion, a price-to-earnings ratio of 36.84, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a 50 day moving average of $14.35 and a two-hundred day moving average of $13.93. Takeda Pharmaceutical has a 52-week low of $12.58 and a 52-week high of $15.37. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts forecast that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of institutional investors have recently made changes to their positions in TAK. Charles Schwab Investment Management Inc. raised its holdings in Takeda Pharmaceutical by 17.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company’s stock valued at $2,661,000 after acquiring an additional 27,628 shares in the last quarter. FMR LLC raised its stake in shares of Takeda Pharmaceutical by 10.9% in the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after purchasing an additional 286,052 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Verition Fund Management LLC acquired a new position in Takeda Pharmaceutical in the third quarter worth about $1,533,000. Finally, Erste Asset Management GmbH bought a new stake in Takeda Pharmaceutical in the third quarter valued at about $52,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.